EBS Technologies GMBH
Stimulating “silent neurons” to restore impaired vision
This article was originally published in Start Up
EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.